Top

Published in:

01-09-2012 | EDUCATIONAL SERIES—BLUE SERIES

The association of annexin A2 and cancers

Authors: Xiaohui Zhang, Shuqing Liu, Chunmei Guo, Junwei Zong, Ming-Zhong Sun

Published in: Clinical and Translational Oncology | Issue 9/2012

Abstract

Annexins are a group of calcium- and phospholipid-dependent proteins. As a member of the annexin, annexin A2 (Anxa2) is widely distributed in nucleus, cytoplasm and extracellular surface and mainly expressed in human endothelial cells, mononuclear cells, macrophages, marrow cells and some tumor cells. Accumulated evidences indicated that Anxa2 deregulation was associated with the occurrence, invasion and metastasis of cancers. Anxa2 up-regulation was related to the development, invasion, metastasis and drug resistance of hepatocellular carcinoma, colorectal cancer, breast cancer, pancreatic cancer, acute promyelocytic leukemia and renal cell carcinoma; while Anxa2 down-regulation was associated with prostate cancer, esophageal squamous carcinoma and nasopharyngeal carcinoma and sinonasal adenocarcinoma. The association between Anxa2 and malignant tumors as well as the potential action mechanisms were summarized in current work. Anxa2 might be used as a potential biomarker for the diagnosis, treatment and prognosis of certain tumors.

Moss SE (2004) The annexins. Genome Biol 5:219PubMedCrossRef

Radke K, Martin GS (1979) Transformation by Rous sarcoma virus: effects of src gene expression on the synthesis and phosphorylation of cellular polypeptides. Proc Natl Acad Sci USA 76:5212–5216PubMedCrossRef

Sarafian T, Pradel LA, Henry JP et al (1991) The participation of annexin II (calpactin I) in calcium-evoked exocytosis requires protein kinase C. J Cell Biol 114:1135–1147PubMedCrossRef

Chiang Y, Rizzino A, Sibenaller ZA et al (1999) Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem 199:139–147PubMedCrossRef

Mussunoor S, Murray GI (2008) The role of annexins in tumour development and progression. J Pathol 216:131–140PubMedCrossRef

Vermeersch H, Loose D, Lahorte C et al (2004) 99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma. Nucl Med Commun 25:259–263PubMedCrossRef

Liu J, Rothermund CA, Ayala-Sanmartin J et al (2003) Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. BMC Biochem 4:10PubMedCrossRef

Jost M, Gerke V (1996) Mapping of a regulatory important site for protein kinase C phosphorylation in the N-terminal domain of annexin II. Biochim Biophys Acta 1313:283–289PubMedCrossRef

Flood EC, Hajjar KA (2011) The annexin A2 system and vascular homeostasis. Vasc Pharmacol 54:59–67CrossRef

10.

Yang LP, Yang ZL, Tan XG et al (2010) Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder. Zhonghua Zhong Liu Za Zhi 32:595–599

11.

Fan X, Yu Z, Liu J et al (2010) Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke 41:S54–S58PubMedCrossRef

12.

Chiang Y (1993) Cycle annexin II expression is regulated during mammalian cell. Cancer Res 53:6017PubMed

13.

Singh P (2007) Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 252:19–35PubMedCrossRef

14.

Zheng L, Foley K, Huang L et al (2011) Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One 6:e19390PubMedCrossRef

15.

Emoto K, Yamada Y, Sawada H et al (2001) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92:1419–1426PubMedCrossRef

16.

Katayama M, Nakano H, Ishiuchi A et al (2006) Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today 36:1085–1093PubMedCrossRef

17.

Ji NY, Park MY, Kang YH et al (2009) Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med 24:765–771PubMed

18.

Kittaka N, Takemasa I, Takeda Y et al (2008) Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur J Cancer 44:885–897PubMedCrossRef

19.

Yu GR, Kim SH, Park SH et al (2007) Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med 39:641–652PubMed

20.

Mohammad HS, Kurokohchi K, Yoneyama H et al (2008) Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 33:1157–1163PubMed

21.

Zhao P, Zhang W, Tang J et al (2010) Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci 101:387–395PubMedCrossRef

22.

Zhao P, Zhang W, Wang SJ et al (2011) HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology 54:2012–2024PubMedCrossRef

23.

Sharma MR, Koltowski L, Ownbey RT et al (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146–156PubMedCrossRef

24.

Chuthapisith S, Layfield R, Kerr ID et al (2007) Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30:1545–1551PubMed

25.

Zhang F, Zhang L, Zhang B et al (2009) Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 8:5041–5047PubMedCrossRef

26.

Sharma M, Ownbey RT, Sharma MC (2010) Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88:278–286PubMedCrossRef

27.

Kim J, Hajjar KA (2002) Annexin II: a plasminogen–plasminogen activator co-receptor. Front Biosci 7:d341–d348PubMedCrossRef

28.

Dassah M, Deora AB, He K et al (2009) The endothelial cell annexin A2 system and vascular fibrinolysis. Gen Physiol Biophys 28 (Spec):F20–F28

29.

Ling Q, Jacovina AT, Deora A et al (2004) Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 113:38–48PubMed

30.

Liu Y, Wang Z, Jiang M et al (2011) The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res 35:879–884

31.

Zhang XH, Hu Y, Bao L et al (2009) Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia. Chin Med J 122:1969–1973PubMed

32.

Domoto T (2006) Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 98:77–82CrossRef

33.

Ohno Y, Izumi M, Kawamura T et al (2009) Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 101:287–294PubMedCrossRef

34.

Tian R, Wei LM, Qin RY et al (2008) Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci 53:65–72PubMedCrossRef

35.

Chung CY, Erickson HP (1994) Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 126:539–548PubMedCrossRef

36.

Chung CY, Murphy-Ullrich JE, Erickson HP (1996) Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Bio Cell 7:883–892

37.

Esposito I, Penzel R, Chaib-Harrireche M et al (2006) Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208:673–685PubMedCrossRef

38.

Lehnigk U, Zimmermann U, Woenckhaus C et al (2005) Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients. Histol Histopath 20:673–680

39.

Stewart J, Fleshner N, Cole H et al (2007) Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol 60:773–780PubMedCrossRef

40.

Yee DS, Narula N, Ramzy I et al (2007) Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med 131:902–908PubMed

41.

Chetcuti A, Margan SH, Russell P et al (2001) Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 61:6331–6334PubMed

42.

Liu JW, Shen JJ, Tanzillo-Swarts A et al (2003) Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22:1475–1485PubMedCrossRef

43.

Ellinger J, Bastian PJ, Jurgan T et al (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71:161–167PubMedCrossRef

44.

Dong Q, Patel M, Scott KF et al (2006) Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240:9–16PubMedCrossRef

45.

Shiozawa Y, Havens AM, Jung Y et al (2008) Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 105:370–380PubMedCrossRef

46.

Qi YJ, Wang LD, Jiao XY et al (2007) Dysregulation of Annexin II expression in esophageal squamous cell cancer and adjacent tissues from a high-incidence area for esophageal cancer in Henan province. Ai Zheng 26:730–736PubMed

47.

Chan CML (2008) Proteomic comparison of nasopharyngeal cancer cell lines C666–1 and NP69 identifies down-regulation of annexin II and 2-tubulin for nasopharyngeal carcinoma. Arch Pathol Lab Med 132:675–683PubMed

48.

Rodrigo JP, Garcia-Pedrero JM, Llorente JL et al (2011) Down-regulation of annexin A1 and A2 protein expression in intestinal-type sinonasal adenocarcinomas. Hum Pathol 42:88–94PubMedCrossRef

49.

Tapia JPR (2007) Annexin A2 Expression in Head and Neck Squamous Cell Carcinoma. Acta Otorrinolaringol Esp 58:257–262CrossRef

50.

Pena-Alonso E, Rodrigo JP, Parra IC et al (2008) Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 263:89–98PubMedCrossRef

Title: The association of annexin A2 and cancers
Authors: Xiaohui Zhang
Shuqing Liu
Chunmei Guo
Junwei Zong
Ming-Zhong Sun
Publication date: 01-09-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0855-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2012

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

In answer to: “Comments to SEOM clinical guidelines for the treatment of thyroid cancer” by Garcilaso Riesco-Eizaguirre et al

Promises and pitfalls of new technology in radiotherapy

Searching for Hif1-α interacting proteins in renal cell carcinoma

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Comments to SEOM clinical guidelines for the treatment of thyroid cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer